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BACKGROUND
Patients who have residual invasive carcinoma after the receipt of neoadjuvant 
chemotherapy for human epidermal growth factor receptor 2 (HER2)–negative 
breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these 
patients remains unclear.
METHODS
We randomly assigned 910 patients with HER2-negative residual invasive breast 
cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or both) 
to receive standard postsurgical treatment either with capecitabine or without 
(control). The primary end point was disease-free survival. Secondary end points 
included overall survival.
RESULTS
The result of the prespecified interim analysis met the primary end point, so this 
trial was terminated early. The final analysis showed that disease-free survival was 
longer in the capecitabine group than in the control group (74.1% vs. 67.6% of the 
patients were alive and free from recurrence or second cancer at 5 years; hazard 
ratio for recurrence, second cancer, or death, 0.70; 95% confidence interval [CI], 
0.53 to 0.92; P = 0.01). Overall survival was longer in the capecitabine group than 
in the control group (89.2% vs. 83.6% of the patients were alive at 5 years; hazard 
ratio for death, 0.59; 95% CI, 0.39 to 0.90; P = 0.01). Among patients with triple-
negative disease, the rate of disease-free survival was 69.8% in the capecitabine 
group versus 56.1% in the control group (hazard ratio for recurrence, second 
cancer, or death, 0.58; 95% CI, 0.39 to 0.87), and the overall survival rate was 
78.8% versus 70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 to 0.90). The hand–
foot syndrome, the most common adverse reaction to capecitabine, occurred in 
73.4% of the patients in the capecitabine group.
CONCLUSIONS
After standard neoadjuvant chemotherapy containing anthracycline, taxane, or 
both, the addition of adjuvant capecitabine therapy was safe and effective in pro-
longing disease-free survival and overall survival among patients with HER2-
negative breast cancer who had residual invasive disease on pathological testing. 
(Funded by the Advanced Clinical Research Organization and the Japan Breast 
Cancer Research Group; CREATE-X UMIN Clinical Trials Registry number, 
UMIN000000843.)
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Patients who have residual invasive breast cancer after the receipt of neoadju-vant chemotherapy have a high risk of re-
lapse.1 The rate of complete response as assessed 
on pathological testing (hereafter, pathological 
complete response) ranges from 13 to 22% among 
patients with human epidermal growth factor 
receptor 2 (HER2)–negative primary breast can-
cer.1 Patients who do not have a pathological 
complete response after the receipt of neoadju-
vant taxane and anthracycline chemotherapy have 
a 20 to 30% risk of relapse.2 Patients with HER2-
negative cancer who receive neoadjuvant chemo-
therapy often receive postoperative radiation 
therapy, whereas endocrine therapy is adminis-
tered to patients with hormone-receptor–positive 
disease only.3,4 No adjuvant chemotherapy has 
been established for patients who have residual 
invasive breast cancer after the receipt of neoad-
juvant chemotherapy.
Capecitabine (Xeloda, Hoffmann–La Roche), 
an oral prodrug of fluorouracil, has been shown 
to be efficacious as adjuvant chemotherapy in 
patients with gastrointestinal cancer.5-7 However, 
its efficacy in patients with breast cancer is un-
clear.8,9 Capecitabine has been shown to be effec-
tive in patients with metastatic breast cancer10-12 
and is often used as second-line monotherapy in 
patients whose disease is resistant to anthra-
cycline, taxane, or both.3,13 We conducted the 
Capecitabine for Residual Cancer as Adjuvant 
Therapy (CREATE-X) trial, which was a multi-
center, open-label, randomized, phase 3 trial 
that was designed to evaluate the efficacy and 
safety of adjuvant capecitabine monotherapy in 
patients with HER2-negative primary breast can-
cer who had residual invasive disease after the 
receipt of standard neoadjuvant chemotherapy 
containing anthracycline, taxane, or both.
Me thods
Patients
The trial protocol (including the statistical analy-
sis plan) is available with the full text of this 
article at NEJM.org. We recruited patients who 
had HER2-negative breast cancer of stage I through 
IIIB and pathologically assessed residual cancer 
cells (no pathological complete response) after 
neoadjuvant chemotherapy with anthracycline, 
taxane, or both (Fig. 1). Patients who had resid-
ual components of ductal carcinoma in situ were 
assessed as having a pathological complete re-
sponse on the basis of the National Surgical 
Adjuvant Breast and Bowel Project criteria.14 Pa-
tients with tumor-positive lymph nodes15 were 
also eligible. Central pathological review inde-
pendently confirmed the presence of residual 
invasive cancer cells. The pathological effect of 
neoadjuvant chemotherapy was graded from 0 to 
3 according to the response criteria of the Japa-
nese Breast Cancer Society.16 Grade 0 indicates 
no response (almost no change in cancer cells 
after treatment), grade 1a a mild response (mild 
changes in cancer cell, regardless of the area, or 
marked changes in cancer cell seen in less than 
one third of cancer cells), grade 1b a moderate 
response (marked changes in one third or more 
but less than two thirds of tumor cells), grade 2 
a marked response (marked changes in two thirds 
or more of tumor cells), and grade 3 a complete 
response (necrosis or disappearance of all tumor 
cells, replacement of all cancer cells by granuloma-
like or fibrous tissue, and, in the case of com-
plete disappearance of cancer cells, pretreatment 
pathological evidence of the presence of cancer).
Other key eligibility criteria were an age of 
20 to 74 years, HER2-negative status (score of 
0 or 1 on an immunohistochemical test [range, 
0 to 3, with a score of 0 or 1 indicating HER2-
negative breast cancer, a score of 2 a marginal 
result, and a score of 3 HER2-positive breast 
cancer; in the case of a marginal result, HER2 
status was examined by means of fluorescence 
in situ hybridization to establish a positive or 
negative result] or a negative result on fluores-
cence in situ hybridization), and an Eastern Co-
operative Oncology Group (ECOG) performance-
status score of 0 or 1 (on a 5-point scale, with 
higher numbers indicating greater disability). 
Key exclusion criteria were the presence of breast 
cancer in both breasts, other malignant condi-
tions or synchronic multiple cancers, and previ-
ous treatment with oral fluorouracil.
Eligible patients were centrally enrolled after 
pathological assessment and were randomly as-
signed in a 1:1 ratio to receive either capecitabine 
plus standard therapy or standard therapy alone 
(control). Randomization was performed at the 
data center with the use of concealed assign-
ments and with the use of a minimization 
method with the following balancing adjustment 
factors: estrogen-receptor status (positive vs. neg-
ative), age (≤50 years vs. >50 years), taxane use 
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(yes vs. no vs. ≥4 cycles of docetaxel and cyclo-
phosphamide), axillary lymph-node metastasis on 
histologic assessment (no nodes vs. 1, 2, or 3 nodes 
vs. ≥4 nodes vs. unknown number), fluorouracil 
use (yes vs. no), and participating institution.
Trial Design and Oversight
The trial treatments were standard postsurgical 
treatments,3,4 which included endocrine therapy 
in patients with estrogen-receptor–positive dis-
ease and radiotherapy (if indicated), with or 
without capecitabine. Endocrine therapy was 
administered as follows: 5 years of tamoxifen 
or toremifene, combined with a gonadotropin-
releasing hormone analogue as needed, in pre-
menopausal patients or 5 years of aromatase 
inhibitors, tamoxifen, or toremifene in post-
menopausal patients. After surgery, the capeci ta-
bine group received oral capecitabine (at a dose of 
1250 mg per square meter of body-surface area, 
twice per day, on days 1 to 14) every 3 weeks for 
six or eight cycles. The concomitant administra-
tion of postsurgical endocrine therapy was al-
lowed. Postsurgical radiotherapy could be given 
before or after randomization and could be con-
comitant with postsurgical endocrine therapy. 
Other anticancer drugs were not allowed until 
recurrence. Follow-up was scheduled through the 
end of the trial. Patients visited the trial institu-
tions every 6 months and underwent mammo-
graphic screening once per year to assess breast-
cancer recurrence.
The trial was designed by the lead authors 
and monitored by an independent data and safety 
monitoring committee. All the patients provided 
written informed consent. The trial was approved 
by the institutional review board at each institu-
tion and conducted in accordance with the Dec-
laration of Helsinki and the ethical guidelines 
for clinical studies of the respective ministries of 
Japan and South Korea. Data were collected and 
centrally monitored at the Comprehensive Sup-
port Project for Oncology Research. To ensure 
data quality, some trial institutions were chosen 
by random sampling for auditing.
All the authors vouch for the accuracy and 
completeness of the data and analyses and for 
the adherence of the trial to the protocol. The 
first draft of the manuscript was prepared by the 
first and last authors with assistance from a 
professional medical writer, funded by the Japan 
Breast Cancer Research Group. All the authors 
made the decision to submit the manuscript for 
publication. The trial was funded by the Ad-
vanced Clinical Research Organization and the 
Japan Breast Cancer Research Group, and the 
Figure 1. Trial Design.
Neoadjuvant chemotherapy involved at least four cycles of an anthracy-
cline. However, if the anthracycline was administered for less than four 
 cycles, one of the following four regimens could be used: fluorouracil and 
epirubicin (at a dose of ≥100 mg per square meter of body-surface area) 
and cyclophosphamide (FEC) for three cycles, followed by docetaxel at a 
dose of 75 mg per square meter for three cycles; FEC for three cycles, fol-
lowed by docetaxel at a dose of 75 mg per square meter and cyclophospha-
mide at a dose of 600 mg per square meter (TC) for three cycles; TC for three 
cycles, followed by FEC for three cycles; or TC only for four cycles. Patients 
who had serious adverse events or disease progression were included if 
they completed at least two cycles of chemotherapy. If patients had positive 
lymph nodes, combined chemotherapy with an anthracycline and taxane 
(docetaxel or paclitaxel, as chosen by the physician) was recommended. 
The Eastern Cooperative Oncology Group (ECOG) performance status is 
scored on a scale of 0 to 5, with 0 indicating no symptoms and higher scores 
indicating greater disability related to tumor. Standard therapy included  
5 years of endocrine therapy for hormone-receptor–positive cancer, no further 
systemic treatment for hormone-receptor–negative cancer, and radiotherapy if 
indicated. HER2 denotes human epidermal growth factor receptor 2.
Neoadjuvant chemotherapy
Patients with HER2-negative stage I–IIIB breast cancer
Age 20–74 yr
ECOG performance-status score of 0 or 1
Surgery
No complete response on pathological
assessment, or a complete response
with positive lymph nodes
Randomization
Capecitabine group, standard
therapy plus capecitabine
1250 mg/m2, twice a day, on days 1–14
Control group,
standard therapy
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sponsors of the trial were the Japan Breast Can-
cer Research Group, the Korean Breast Cancer 
Society, and the Korean Cancer Study Group. 
The funders and sponsors had no role in the 
trial design, data collection and analysis, or the 
interpretation of the results. In South Korea, 
capecitabine was provided free of charge by Roche 
Korea, which had no other role in the trial. In 
Japan, supply of capecitabine by a pharmaceuti-
cal company for use in a clinical trial is not per-
mitted by law, and capecitabine was administered 
to patients in accordance with health insurance 
provisions (national or public health insurance 
covered ≥70% of the cost, and the remainder 
was paid by private health insurance or others).
End Points
The primary end point of the trial was disease-
free survival, which was defined as the time from 
randomization to recurrence, the development 
of a second cancer, or death from any cause. 
Secondary end points included overall survival, 
which was defined as the time from randomiza-
tion to death from any cause. Data for patients 
who did not have an event of interest were cen-
sored at the date of the last follow-up. For the 
safety evaluation, adverse events that occurred 
within 6 months after randomization were as-
sessed and reported according to a list of known 
adverse reactions to capecitabine and were graded 
according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, 
version 3.0.17 Events of the hand–foot syndrome 
were graded from 1 to 3, with higher grades 
indicating more severe symptoms or disability 
(see the Supplementary Appendix, available at 
NEJM.org).10
Statistical Analysis
Survival curves were estimated with the use of 
the Kaplan–Meier method, and hazard ratios 
with 95% confidence intervals were determined 
with the use of a Cox proportional-hazards 
model. On the basis of the Cox model, prespeci-
fied subgroup analyses for important background 
or prognostic factors were conducted. Additional 
post hoc subgroup analyses of body-mass index 
(the weight in kilograms divided by the square of 
the height in meters) in all patients and of body-
mass index in patients with hormone-receptor–
negative disease were conducted. For the safety 
analysis, the numbers and percentages of patients 
with adverse events of each grade were calculated.
The primary efficacy analysis was performed 
on the full analysis set according to the intention-
to-treat principle. The full analysis set included 
all the patients who had undergone randomiza-
tion except those who did not meet any of the 
major eligibility criteria (e.g., because of errors 
in assignment of clinical stage of cancer before 
neoadjuvant chemotherapy) and those without any 
follow-up data after randomization. Sensitivity 
analyses were performed in the per-protocol 
population, which included patients from the 
full analysis set who received the trial treatment 
per the protocol and fulfilled all minor eligibil-
ity criteria (e.g., with regard to range of labora-
tory examinations at registration). The safety 
population included all the patients who started 
the trial treatment.
The hazard ratio for recurrence, second can-
cer, or death in the analysis of disease-free sur-
vival in the capecitabine group was assumed 
to be 0.74.14,18-21 With the recruitment period set 
at 5 years, the follow-up period at a maximum of 
5 years, the beta level at 0.2, and the alpha 
level at 0.05 (two-sided), we calculated that the 
trial would need to include 427 patients in each 
group.22 Thus, we planned to enroll 900 patients 
(450 patients per group). Interim safety analyses 
were prespecified in order to investigate the 
dose of capecitabine and number of cycles that 
could be received with an acceptable safety pro-
file. An interim efficacy analysis of disease-free 
survival with the use of the Lan–DeMets alpha-
spending function method (O’Brien–Fleming 
type)23 was prespecified to occur at 2 years after 
the enrollment of patients was complete. A one-
sided P value (at a significance level of 0.025) 
was used for decision making in all the analyses, 
and two-sided P values (at a significance level of 
0.05) are provided in this article, according to 
usual practice.
R esult s
Patients
From February 2007 through July 2012, a total of 
910 patients (606 patients from 62 institutions 
in Japan and 304 patients from 22 institutions in 
South Korea) were enrolled (see the Supplemen-
tary Appendix). Patients were randomly assigned 
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equally to the capecitabine group and the con-
trol group (455 patients in each group). This trial 
was registered late owing to an administrative 
error, and the registration information was dis-
closed on November 1, 2007. At the time of 
registration, 19 patients had been enrolled.
After the exclusion of patients for ineligibility 
(16 patients), withdrawal of informed consent 
(3), violation of informed consent (2), and lack 
of follow-up data (2), a total of 887 patients were 
included in the full analysis set (443 patients in 
the capecitabine group and 444 in the control 
group). One patient in the capecitabine group 
did not receive the assigned capecitabine but 
received control therapy instead, and 1 patient 
assigned to the control group received capeci-
tabine instead. These patients were included in 
the originally assigned groups in the intention-
to-treat analysis of efficacy. In the safety analy-
sis, however, these patients were included in the 
group according to the actual regimen received. 
A total of 844 patients (415 patients in the 
capecitabine group and 429 in the control group) 
were included in the per-protocol set. Details are 
provided in Figure S1 in the Supplementary Ap-
pendix.
The characteristics of the patients at baseline 
were similar in the two groups (Table 1). The 
median age of the patients was 48 years (range, 
25 to 74). Approximately 40% of the patients had 
stage IIIA or IIIB breast cancer, and 32.2% had 
triple-negative breast cancer (i.e., negative for 
estrogen receptors, progesterone receptors, and 
HER2). A total of 95.3% of the patients had re-
ceived an anthracycline and taxane as neoadju-
vant chemotherapy (82.2% of the patients had 
received sequential therapy and 13.1% had re-
ceived concurrent therapy).
On the basis of the interim safety analysis 
involving the first 50 patients who were treated 
with six cycles of capecitabine, the independent 
data and safety monitoring committee recom-
mended in January 2010 that the capecitabine 
treatment be extended to eight cycles (24 weeks). 
Consequently, 159 patients were treated with six 
cycles of capecitabine and 283 with eight cycles, 
of whom 57.9% and 37.8%, respectively, com-
pleted capecitabine treatment with the planned 
dose, 23.9% and 36.7% completed capecitabine 
treatment with dose reduction, and 18.2% and 
25.4% discontinued capecitabine treatment. The 
mean relative dose intensity was 87.9% in pa-
tients who received six cycles and 78.7% in those 
who received eight cycles.
Disease-free Survival and Overall Survival
The prespecified interim efficacy analysis that 
was conducted on March 11, 2015, showed that 
the primary end point was met, so the indepen-
dent data and safety monitoring committee rec-
ommended early termination of the trial as 
specified in the protocol. Therefore, this trial was 
terminated early, and data up to the data-cutoff 
date of September 30, 2015, were fixed on June 
16, 2016, and were included in the final analysis 
performed on July 28, 2016. The median follow-
up was 3.6 years.
The rate of disease-free survival was higher in 
the capecitabine group than in the control group 
(82.8% vs. 73.9% of the patients were alive and 
free from recurrence or second cancer at 3 years, 
and 74.1% vs. 67.6% were alive and free from 
recurrence or second cancer at 5 years), and the 
time to recurrence, second cancer, or death was 
longer in the capecitabine group than in the con-
trol group (hazard ratio for recurrence, second 
cancer, or death, 0.70; 95% confidence interval 
[CI], 0.53 to 0.92; P = 0.01) (Fig. 2A). The overall 
survival rate was higher in the capecitabine 
group than in the control group (94.0% vs. 
88.9% of the patients were alive at 3 years, and 
89.2% vs. 83.6% were alive at 5 years), and sur-
vival was longer in the capecitabine group than 
in the control group (hazard ratio for death, 
0.59; 95% CI, 0.39 to 0.90; P = 0.01). The median 
survival for any end point was not reached in 
either group (Fig. 2B).
The results of the sensitivity analyses regard-
ing disease-free survival and overall survival in the 
per-protocol population were similar to those in 
the full analysis set (Fig. S2 in the Supplemen-
tary Appendix). The benefits of capecitabine 
with regard to disease-free survival and overall 
survival were consistent across the prespecified 
subgroups (Fig. 3, and Fig. S3 in the Supplemen-
tary Appendix). Among patients with hormone-
receptor–negative (triple-negative) disease, the rate 
of disease-free survival was 69.8% in the capeci-
tabine group, as compared with 56.1% in the 
control group (hazard ratio for recurrence, sec-
ond cancer, or death, 0.58; 95% CI, 0.39 to 0.87), 
and the overall survival rate was 78.8% versus 
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Characteristic
Capecitabine Group 
(N = 443)
Control Group 
(N = 444)
Age at enrollment — yr
Median 48 48
Range 25–74 25–74
Menopausal status — no. (%)
Premenopausal 262 (59.1) 248 (55.9)
Postmenopausal 181 (40.9) 196 (44.1)
Body-mass index†
Median 22.6 23.0
Range 15.6–39.9 15.6–41.2
Tumor size at diagnosis — no./total no. (%)
≤2 cm 68/442 (15.4) 61/444 (13.7)
>2 to ≤5 cm 244/442 (55.2) 275/444 (61.9)
>5 cm 65/442 (14.7) 69/444 (15.5)
Skin or chest-wall infiltration of any size — no./total no. (%) 65/442 (14.7) 39/444 (8.8)
Hormone-receptor status — no. (%)
Estrogen-receptor positive or progesterone-receptor positive 304 (68.6) 297 (66.9)
Estrogen-receptor negative and progesterone-receptor negative 139 (31.4) 147 (33.1)
Neoadjuvant chemotherapy — no. (%)
Sequential anthracycline and taxane 357 (80.6) 372 (83.8)
Concurrent anthracycline and taxane 63 (14.2) 53 (11.9)
Anthracycline-containing chemotherapy only or docetaxel and cyclophosphamide only 23 (5.2) 19 (4.3)
Fluorouracil plus anthracycline‡ 262 (59.1) 271 (61.0)
Pathological-effect grade — no./total no. (%)§
0 19/434 (4.4) 13/435 (3.0)
1a or 1b 232/434 (53.5) 220/435 (50.6)
2 or 3 183/434 (42.2) 202/435 (46.4)
No. of lymph nodes involved on histologic assessment — no. (%)
0 176 (39.7) 171 (38.5)
1–3 165 (37.2) 174 (39.2)
≥4 102 (23.0) 99 (22.3)
Adjuvant endocrine therapy — no. (%)
Yes 298 (67.3) 304 (68.5)
No 145 (32.7) 140 (31.5)
Radiotherapy — no. (%)¶
Yes 321 (72.5) 326 (73.4)
No 122 (27.5) 118 (26.6)
*  There were no significant differences between the two groups. The following adjustment factors were used to balance randomization with 
the use of a minimization method: estrogen-receptor status (positive vs. negative), age (≤50 years vs. >50 years), taxane use (yes vs. no vs. 
≥4 cycles of docetaxel and cyclophosphamide), axillary lymph-node metastasis on histologic assessment (no nodes vs. 1, 2, or 3 nodes vs. 
≥4 nodes vs. unknown number), fluorouracil use (yes vs. no), and participating institution.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Fluorouracil was administered intravenously as a bolus dose.
§  The pathological effect of neoadjuvant chemotherapy was graded from 0 to 3 according to the response criteria of the Japanese Breast Cancer 
Society.16 Grade 0 indicates no response (almost no change in cancer cells after treatment), grade 1 slight response, grade 1a a mild response 
(mild changes in cancer cells regardless of the area, or marked changes in cancer cell seen in less than one third of cancer cells), grade 1b  
a moderate response (marked changes in one third or more but less than two thirds of tumor cells), grade 2 a marked response (marked 
changes in two thirds or more of tumor cells), and grade 3 a complete response (necrosis or disappearance of all tumor cells, replacement 
of all cancer cells by granuloma-like or fibrous tissue, and, in the case of complete disappearance of cancer cells, pretreatment pathological 
evidence of the presence of cancer).
¶  Radiotherapy was for the following regions: conserving breast only, conserving breast and regional lymph nodes, chest wall or regional 
lymph nodes, and unknown region.
Table 1. Characteristics of the Patients at Baseline.*
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70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 
to 0.90) (Fig. 2C and 2D). Among patients with 
hormone-receptor–positive disease, the rate of 
disease-free survival was 76.4% in the capeci-
tabine group, as compared with 73.4% in the 
control group (hazard ratio for recurrence, sec-
ond cancer, or death, 0.81; 95% CI, 0.55 to 1.17), 
and the overall survival rate was 93.4% versus 
90.0% (hazard ratio for death, 0.73; 95% CI, 0.38 
to 1.40) (Fig. S4A and S4B in the Supplementary 
Appendix). Post hoc subgroup analyses of dis-
ease-free survival and overall survival showed no 
significant interaction between the subgroup of 
patients with a high body-mass index (≥25.0) 
and the subgroup of those with a low body-mass 
index (<25.0) (Fig. 3, and Fig. S3 in the Supple-
mentary Appendix).
Safety
All the patients who started the trial treatment 
were included in the safety analysis (443 patients 
in the capecitabine group and 459 in the control 
group) (Table 2). In the capecitabine group, the 
hand–foot syndrome was the most frequent ad-
verse event, occurring in 325 patients (73.4%), 
including 49 patients (11.1%) with a grade 3 
event. The common hematologic adverse events 
(occurring in >40% of patients) in the capeci ta-
bine group were leukopenia, thrombocytopenia, 
neutropenia, and anemia. The common nonhema-
tologic adverse events (occurring in >20% of 
patients) in the capecitabine group were fatigue, 
nausea, diarrhea, stomatitis, and increases in 
the alanine aminotransferase, bilirubin, lactate 
dehydrogenase, aspartate aminotransferase, and 
alkaline phosphatase levels. Most adverse events 
were grade 1 or 2 in severity. In the capecitabine 
group, neutropenia of grade 3 or 4 was noted in 
6.3% of the patients, diarrhea of grade 3 or 4 in 
2.9%, and leukopenia of grade 3 or 4 in 1.6%. 
Serious adverse events that were considered by 
the investigators to be related to capecitabine 
occurred in 4 patients, including neutropenia 
and diarrhea in 1 patient and epigastric pain, 
abdominal pain, and diarrhea in 1 patient each. 
All the serious adverse events resolved and were 
nonfatal.
Discussion
This trial showed that capecitabine that was 
administered as a postoperative adjuvant therapy 
after neoadjuvant chemotherapy in patients with 
residual invasive tumors or lymph-node metasta-
sis prolonged disease-free survival and overall 
survival. Two aspects of this trial may account 
for the positive result. First, the trial targeted a 
population of patients who did not have a patho-
logical complete response, a group whose sur-
vival outcomes are known to be unfavorable. 
Among patients who did not have a pathological 
complete response, more than 20% have a re-
lapse within 5 years,2 and approximately half the 
patients with triple-negative disease have recur-
rence.1 We excluded patients who had a patho-
logical complete response, who were likely to 
be cured with standard chemotherapy regimens. 
Therefore, this exclusion enriched the trial popu-
lation for patients who may benefit from addi-
tional therapy.
Second, this trial used an effective schedule 
of the fluorouracil-based antimetabolite; capeci-
tabine therapy was compared with no chemo-
therapy as postoperative adjuvant therapy. In 
fact, 60% of the patients in our trial had residu-
al invasive cancer after receiving an intravenous 
bolus infusion of fluorouracil as a component of 
neoadjuvant chemotherapy. Furthermore, a work-
ing hypothesis was formed regarding the mech-
anism of drug-combination effect. Anthracyclines 
and taxanes are able to induce thymidine phos-
phorylase, an enzyme that activates capecitabine.24 
Chemotherapeutic agents may have schedule de-
pendency.25-28 In particular, fluorouracil has been 
shown to be schedule-dependent. Fluorouracil is 
a phase-specific antimetabolite with a short half-
life, and infusional schedules and oral drugs have 
been developed to enhance its efficacy.29
However, several trials of adjuvant capecitabine 
that was administered in combination with chemo-
therapy did not show an advantage over regi-
mens without capecitabine.8,9,30-32 In the GEICAM/ 
2003-10 trial conducted by Grupo Español de 
Investigacíon en Cáncer de Mama (Spanish Breast 
Cancer Group), invasive disease–free survival was 
significantly longer among patients with node-
positive early breast cancer who received adju-
vant epirubicin and cyclophosphamide followed 
by docetaxel than among those who received 
adjuvant epirubicin and docetaxel followed by 
capecitabine.8 In the Finland Capecitabine Trial 
(FinXX), the integration of capecitabine into adju-
vant docetaxel therapy followed by cyclophospha-
mide and epirubicin did not prolong recurrence-
free survival, as compared with adjuvant docetaxel 
followed by cyclophosphamide, epirubicin, and 
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fluorouracil.9 Furthermore, although the prima-
ry end point of disease-free survival was not met 
in a phase 3 adjuvant trial33 comparing doxoru-
bicin plus cyclophosphamide followed by doce-
taxel plus capecitabine with doxorubicin plus 
cyclophosphamide followed by docetaxel alone, 
a significant prolongation in overall survival, a 
secondary end point, was seen with the combi-
nation of docetaxel plus capecitabine. The major-
ity of the patients included in the trial had a low 
risk of recurrence, as identified by estrogen-
receptor–positive status and low Ki67 status.33
Moreover, the percentages of patients with 
triple-negative disease also differed in the two 
trials.8,9 In the GEICAM/2003-10 trial, 12% of the 
patients had triple-negative disease, and no su-
periority of a capecitabine-containing adjuvant 
regimen was shown, as compared with control 
(hazard ratio for death or recurrence with inva-
sive disease, 1.19; 95% CI, 0.70 to 2.04).8 In 
Figure 2. Kaplan–Meier Estimates of Disease-free Survival and Overall Survival.
Panels A and B show disease-free survival and overall survival, respectively, in the full analysis set (primary analysis). Tick marks indicate 
censored data. Panels C and D show disease-free survival and overall survival, respectively, in the subgroup of patients with triple-negative 
breast cancer (i.e., breast cancer that was negative for estrogen receptors, progesterone receptors, and HER2).
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Figure 3. Subgroup Analysis of Disease-free Survival in the Full Analysis Set.
On the basis of the Cox model, prespecified subgroup analyses for background or prognostic factors were conduct-
ed to estimate hazard ratios with 95% confidence intervals and to test for interaction among subgroups with the use 
of two-sided P values. Post hoc subgroup analyses were conducted regarding body-mass index (BMI; the weight in 
kilograms divided by the square of the height in meters) in all patients and BMI in patients with hormone-receptor–
negative disease. A tumor size of cT4 indicates a tumor of any size with direct extension to the chest wall or skin. 
Data on tumor size were missing for one patient in the capecitabine group. The pathological effect of neoadjuvant 
chemotherapy was graded from 0 to 3 according to the response criteria of the Japanese Breast Cancer Society16: 
grade 0 indicates no response, grade 1a a mild response, grade 1b a moderate response, grade 2 a marked response, 
and grade 3 a complete response. Data on pathological effect were missing for nine patients in each group. Arrows 
indicate that the limits of the confidence interval are not shown.
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FinXX, 13% of the patients had triple-negative 
cancer, and recurrence-free survival was longer 
with the capecitabine-containing regimen than 
with control (hazard ratio for recurrence or death, 
0.48; 95% CI, 0.26 to 0.88).9 In our trial, 30% 
of the patients had triple-negative disease. The 
prolongation with capecitabine versus control in 
disease-free survival (hazard ratio for recurrence, 
second cancer, or death, 0.58) and overall sur-
vival (hazard ratio for death, 0.52) was particu-
larly notable among patients with triple-negative 
disease. Among patients with hormone-receptor–
positive disease, we observed a similar tendency 
with a reduced magnitude (hazard ratio for recur-
rence, second cancer, or death, 0.81; hazard ratio 
for death, 0.73). A randomized trial by Coalición 
Iberoamericana de Investigación en Oncología 
Mamaria (CIBOMA/2004-01/GEICAM/2003-11; 
ClinicalTrials.gov number, NCT00130533), which 
has a design similar to that used in our trial, is 
currently in progress to evaluate the efficacy of 
adjuvant capecitabine after standard chemother-
apy in patients with triple-negative cancer.34
With respect to safety, the known adverse reac-
tions of capecitabine occurred frequently in our 
trial, although most reactions were not severe. 
The hand–foot syndrome — the most common 
adverse reaction of capecitabine — occurred in 
nearly 75% of the patients who received 
capecitabine. Other common events were myelo-
toxic effects, hepatic dysfunction, and gastroin-
testinal symptoms. The doses of capecitabine 
that were used in our trial were within the range 
that has been approved in Western countries. In 
accordance with international standards,35 the 
following dosing regimen was used for capeci-
tabine: 1250 mg per square meter, twice per day, 
on days 1 to 14 every 3 weeks, followed by 
1-week withdrawal. Although some patients had 
a dose reduction or withdrawal of capecitabine 
because of adverse events (mainly the hand–foot 
syndrome), the relative dose intensity in approxi-
mately 80% of the patients was maintained dur-
ing the treatment period of six or eight cycles. 
For gastrointestinal cancer, the gastrointestinal 
toxicity of fluoropyrimidines (including capecita-
bine) has been reported to be lower in Asian 
patients than in white patients.36,37 In addition, 
the pharmacokinetic profile of capecitabine may 
differ slightly between Asians and non-Asians; 
therefore, racial differences in the safety profile 
of capecitabine after standard anthracycline or 
taxane chemotherapy need to be carefully con-
sidered in patients with breast cancer. With a 
suitable modification of dose or schedule to man-
age the toxic effects of capecitabine, the results of 
our trial are expected to be applicable to patients 
in Western countries.
In conclusion, capecitabine showed effective-
ness as an adjuvant option in patients with 
HER2-negative breast cancer who had residual in-
vasive disease after standard neoadjuvant chemo-
therapy. Our trial showed that adjuvant capecita-
bine therapy prolonged disease-free survival and 
overall survival among patients with breast cancer 
who had a poor prognosis, including those with 
triple-negative disease, and was associated with 
expected toxic effects.
Presented in part at the Annual Meetings of the San Antonio 
Breast Cancer Symposium (SABCS), San Antonio, TX. The first 
interim analysis for safety was presented at the 36th Annual 
Meeting of the SABCS, December 10–14, 2013, and the first ef-
ficacy analysis at the 38th Annual Meeting of the SABCS, De-
cember 8–12, 2015.
Supported by a grant from the Advanced Clinical Research 
Organization and by the Japan Breast Cancer Research Group.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients who participated in this trial and their 
families; Dr. Takashi Inamoto (Tenri Health Care University), 
Dr. Hajime Abe (Bell Land General Hospital), Dr. Akira Yoshioka 
(Mitsubishi Kyoto Hospital), and Dr. Satoshi Morita (Kyoto Uni-
versity Graduate School of Medicine) for serving as members of 
the independent data and safety monitoring committee; Dr. 
Seigo Nakamura (Showa University Hospital); Dr. Jo Anne Zu-
jewski (Bethesda, MD) for suggestions and assistance; and Kae 
Uetani (Statcom, Tokyo) for assistance with an earlier version of 
the manuscript.
Appendix
The authors’ full names and academic degrees are as follows: Norikazu Masuda, M.D., Ph.D., Soo-Jung Lee, M.D., Ph.D., Shoichiro 
Ohtani, M.D., Ph.D., Young-Hyuck Im, M.D., Ph.D., Eun-Sook Lee, M.D., Ph.D., Isao Yokota, Ph.D., Katsumasa Kuroi, M.D., Ph.D., 
Seock-Ah Im, M.D., Ph.D., Byeong-Woo Park, M.D., Ph.D., Sung-Bae Kim, M.D., Ph.D., Yasuhiro Yanagita, M.D., Ph.D., Shinji Ohno, 
M.D., Ph.D., Shintaro Takao, M.D., Ph.D., Kenjiro Aogi, M.D., Ph.D., Hiroji Iwata, M.D., Ph.D., Joon Jeong, M.D., Ph.D., Aeree Kim, 
M.D., Ph.D., Kyong-Hwa Park, M.D., Ph.D., Hironobu Sasano, M.D., Ph.D., Yasuo Ohashi, Ph.D., and Masakazu Toi, M.D., Ph.D.
The authors’ affiliations are as follows: the National Hospital Organization Osaka National Hospital, Osaka (N.M.), Hiroshima City 
Hiroshima Citizens Hospital, Hiroshima (S. Ohtani), Kyoto Prefectural University of Medicine (I.Y.), and Graduate School of Medicine, 
Kyoto University (M.T.), Kyoto, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital (K.K.), and Chuo 
University (Y.O.), Tokyo, Gunma Prefectural Cancer Center, Ota (Y.Y.), National Hospital Organization Kyushu Cancer Center, Fukuoka 
(S. Ohno), Hyogo Cancer Center, Akashi (S.T.), National Hospital Organization Shikoku Cancer Center, Matsuyama (K.A.), Aichi Can-
n engl j med 376;22 nejm.org June 1, 20172158
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
cer Center Hospital, Nagoya (H.I.), and Tohoku University, Sendai (H.S.) — all in Japan; and Yeungnam University Hospital, Daegu 
(S.-J.L.), Samsung Medical Center, Sungkyunkwan University School of Medicine (Y.-H.I.), Cancer Research Institute, Seoul National 
University Hospital, Seoul National University College of Medicine (S.-A.I.), Severance Hospital (B.-W.P.) and Gangnam Severance 
Hospital (J.J.), Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Korea 
University Guro Hospital (A.K.), and Korea University Anam Hospital (K.-H.P.), Seoul, and National Cancer Center, Goyang-si (E.-S.L.) 
— all in South Korea.
References
1. Cortazar P, Zhang L, Untch M, et al. 
Pathological complete response and long-
term clinical benefit in breast cancer: the 
CTNeoBC pooled analysis. Lancet 2014; 
384: 164-72.
2. Kuroi K, Toi M, Ohno S, et al. Prog-
nostic significance of subtype and patho-
logic response in operable breast cancer; 
a pooled analysis of prospective neoadju-
vant studies of JBCRG. Breast Cancer 2015; 
22: 486-95.
3. National Comprehensive Cancer Net-
work. Clinical practice guidelines in on-
cology (NCCN guidelines): breast cancer 
version 2. 2016 (https:/ / www .nccn .org/ 
professionals/ physician_gls/ pdf/ breast .pdf).
4. Coates AS, Winer EP, Goldhirsch A, 
et al. Tailoring therapies — improving the 
management of early breast cancer: St 
Gallen International Expert Consensus on 
the Primary Therapy of Early Breast Can-
cer 2015. Ann Oncol 2015; 26: 1533-46.
5. Twelves C, Wong A, Nowacki MP, et al. 
Capecitabine as adjuvant treatment for 
stage III colon cancer. N Engl J Med 2005; 
352: 2696-704.
6. Bang YJ, Kim YW, Yang HK, et al. Ad-
juvant capecitabine and oxaliplatin for 
gastric cancer after D2 gastrectomy 
(CLASSIC): a phase 3 open-label, random-
ised controlled trial. Lancet 2012; 379: 315-
21.
7. Noh SH, Park SR, Yang HK, et al. Ad-
juvant capecitabine plus oxaliplatin for 
gastric cancer after D2 gastrectomy 
(CLASSIC): 5-year follow-up of an open-
label, randomised phase 3 trial. Lancet 
Oncol 2014; 15: 1389-96.
8. Martín M, Ruiz Simón A, Ruiz Bor-
rego M, et al. Epirubicin plus cyclophos-
phamide followed by docetaxel versus 
epirubicin plus docetaxel followed by 
capecitabine as adjuvant therapy for node-
positive early breast cancer: results from 
the GEICAM/2003-10 study. J Clin Oncol 
2015; 33: 3788-95.
9. Joensuu H, Kellokumpu-Lehtinen PL, 
Huovinen R, et al. Adjuvant capecitabine, 
docetaxel, cyclophosphamide, and epiru-
bicin for early breast cancer: final analy-
sis of the randomized FinXX trial. J Clin 
Oncol 2012; 30: 11-8.
10. Blum JL, Jones SE, Buzdar AU, et al. 
Multicenter phase II study of capecitabine 
in paclitaxel-refractory metastatic breast 
cancer. J Clin Oncol 1999; 17: 485-93.
11. Miles D, von Minckwitz G, Seidman 
AD. Combination versus sequential single-
agent therapy in metastatic breast cancer. 
Oncologist 2002; 7: Suppl 6: 13-9.
12. Geyer CE, Forster J, Lindquist D, et al. 
Lapatinib plus capecitabine for HER2-
positive advanced breast cancer. N Engl J 
Med 2006; 355: 2733-43.
13. Pallis AG, Boukovinas I, Ardavanis A, 
et al. A multicenter randomized phase 
III trial of vinorelbine/gemcitabine dou-
blet versus capecitabine monotherapy 
in anthracycline- and taxane-pretreated 
women with metastatic breast cancer. 
Ann Oncol 2012; 23: 1164-9.
14. Bear HD, Anderson S, Smith RE, et al. 
Sequential preoperative or postoperative 
docetaxel added to preoperative doxorubi-
cin plus cyclophosphamide for operable 
breast cancer: National Surgical Adjuvant 
Breast and Bowel Project Protocol B-27. 
J Clin Oncol 2006; 24: 2019-27.
15. Edge S, Byrd DR, Compton CC, Fritz 
AG, Greene FL, Trotti A, eds. AJCC can-
cer staging manual. 7th ed. New York: 
Springer, 2011.
16. Kuroi K, Toi M, Tsuda H, Kurosumi 
M, Akiyama F. Issues in the assessment of 
the pathologic effect of primary systemic 
therapy for breast cancer. Breast Cancer 
2006; 13: 38-48.
17. National Cancer Institute. Common 
terminology criteria for adverse events 
(CTCAE) v3.0. August 9, 2006 (http://ctep 
.cancer .gov/ protocolDevelopment/ electronic 
_applications/ docs/ ctcaev3 .pdf).
18. Morimoto T, Ogawa M, Orita K, et al. 
Postoperative adjuvant randomised trial 
comparing chemoendocrine therapy, che-
motherapy and immunotherapy for pa-
tients with stage II breast cancer: 5-year 
results from the Nishinihon Cooperative 
Study Group of Adjuvant Chemoendo-
crine Therapy for Breast Cancer (ACETBC) 
of Japan. Eur J Cancer 1996; 32A: 235-42.
19. Early Breast Cancer Trialists’ Collab-
orative Group. Tamoxifen for early breast 
cancer: an overview of the randomised 
trials. Lancet 1998; 351: 1451-67.
20. Taguchi T, Terasawa T, Abe O, Yoshida 
Y, Tominaga T, Ogawa N. A comparative 
study of 5′-DFUR and tegafur in recurrent 
breast cancer. Gan To Kagaku Ryoho 
1985; 12: 2052-60. (In Japanese.)
21. Iwata H, Nakamura S, Toi M, et al. 
Interim analysis of a phase II trial of cy-
clophosphamide, epirubicin and 5-fluoro-
uracil (CEF) followed by docetaxel as pre-
operative chemotherapy for early stage 
breast carcinoma. Breast Cancer 2005; 12: 
99-103.
22. Schoenfeld DA, Richter JR. Nomo-
grams for calculating the number of pa-
tients needed for a clinical trial with sur-
vival as an endpoint. Biometrics 1982; 38: 
163-70.
23. DeMets DL, Lan KK. Interim analysis: 
the alpha spending function approach. 
Stat Med 1994; 13: 1341-52.
24. Toi M, Atiqur Rahman M, Bando H, 
Chow LW. Thymidine phosphorylase 
(platelet-derived endothelial-cell growth 
factor) in cancer biology and treatment. 
Lancet Oncol 2005; 6: 158-66.
25. Romond EH, Perez EA, Bryant J, et al. 
Trastuzumab plus adjuvant chemotherapy 
for operable HER2-positive breast cancer. 
N Engl J Med 2005; 353: 1673-84.
26. Sparano JA, Zhao F, Martino S, et al. 
Long-term follow-up of the E1199 phase 
III trial evaluating the role of taxane and 
schedule in operable breast cancer. J Clin 
Oncol 2015; 33: 2353-60.
27. Moebus V, Jackisch C, Lueck HJ, et al. 
Intense dose-dense sequential chemother-
apy with epirubicin, paclitaxel, and cyclo-
phosphamide compared with convention-
ally scheduled chemotherapy in high-risk 
primary breast cancer: mature results of 
an AGO phase III study. J Clin Oncol 2010; 
28: 2874-80.
28. Ellis GK, Barlow WE, Gralow JR, et al. 
Phase III comparison of standard doxo-
rubicin and cyclophosphamide versus 
weekly doxorubicin and daily oral cyclo-
phosphamide plus granulocyte colony-
stimulating factor as neoadjuvant therapy 
for inf lammatory and locally advanced 
breast cancer: SWOG 0012. J Clin Oncol 
2011; 29: 1014-21.
29. Leichman CG. Schedule dependency of 
5-fluorouracil. Oncology (Williston Park) 
1999; 13: Suppl 3: 26-32.
30. Bear HD, Tang G, Rastogi P, et al. 
Neoadjuvant plus adjuvant bevacizumab 
in early breast cancer (NSABP B-40 [NRG 
Oncology]): secondary outcomes of a phase 
3, randomised controlled trial. Lancet 
Oncol 2015; 16: 1037-48.
31. von Minckwitz G, Rezai M, Loibl S, et al. 
Capecitabine in addition to anthracycline- 
and taxane-based neoadjuvant treatment 
in patients with primary breast cancer: 
phase III GeparQuattro study. J Clin On-
col 2010; 28: 2015-23.
32. Ohno S, Chow LW, Sato N, et al. Ran-
domized trial of preoperative docetaxel 
with or without capecitabine after 4 cycles 
of 5-fluorouracil–epirubicin–cyclophospha-
mide (FEC) in early-stage breast cancer: 
exploratory analyses identify Ki67 as a 
predictive biomarker for response to neo-
adjuvant chemotherapy. Breast Cancer Res 
Treat 2013; 142: 69-80.
n engl j med 376;22 nejm.org June 1, 2017 2159
Capecitabine for Breast Cancer after Chemother apy
33. O’Shaughnessy J, Koeppen H, Xiao Y, 
et al. Patients with slowly proliferative 
early breast cancer have low five-year re-
currence rates in a phase III adjuvant trial 
of capecitabine. Clin Cancer Res 2015; 21: 
4305-11.
34. Lluch A, Gomez H, Ruiz-Borrego M, 
et al. First safety data from a randomised 
phase III (CIBOMA 2004- 01/GEICAM 
2003-11) trial assessing adjuvant capeci ta-
bine maintenance therapy after standard 
chemotherapy for triple-negative early 
breast cancer. Presented at the 33rd An-
nual San Antonio Breast Cancer Sympo-
sium, San Antonio, TX, December 8–12, 
2010. abstract.
35. Mackean M, Planting A, Twelves C, 
et al. Phase I and pharmacologic study of 
intermittent twice-daily oral therapy with 
capecitabine in patients with advanced 
and/or metastatic cancer. J Clin Oncol 
1998; 16: 2977-85.
36. Ma Y, Tang L, Wang HX, Xu YC, Ma Y, 
Zhang FC. Capecitabine for the treatment 
for advanced gastric cancer: efficacy, 
safety and ethnicity. J Clin Pharm Ther 
2012; 37: 266-75.
37. Haller DG, Cassidy J, Clarke SJ, et al. 
Potential regional differences for the tol-
erability profiles of fluoropyrimidines. 
J Clin Oncol 2008; 26: 2118-23.
Copyright © 2017 Massachusetts Medical Society.
an nejm app for iphone
The NEJM Image Challenge app brings a popular online feature to the smartphone. 
Optimized for viewing on the iPhone and iPod Touch, the Image Challenge app lets 
you test your diagnostic skills anytime, anywhere. The Image Challenge app 
randomly selects from 300 challenging clinical photos published in NEJM,  
with a new image added each week. View an image, choose your answer,  
get immediate feedback, and see how others answered.  
The Image Challenge app is available at the iTunes App Store.
Reproduced with permission of copyright owner.
Further reproduction prohibited without
permission.
